GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders... Show more
GeneDx Holdings Corp., a leader in rare-disease and pediatric genomic diagnostics, is in the middle of a deliberate shift from volume-driven growth toward profitable, "paid" volume. That makes this quarter especially important: it reveals whether the company's revenue-cycle management (RCM) transformation — the process of improving how tests are billed, collected, and reimbursed — is translating into stronger margins and collections, even as it temporarily weighs on reported test volume. Coming off a volatile first half that included a Fabric Genomics impairment and a guidance reset, investors are closely watching whether higher reimbursement rates, rising gross margins, and positive adjusted net income can restore confidence in a durable, self-sustaining growth trajectory.
GeneDx posted third quarter 2026 total revenue of $123.1 million, a 5% increase from $116.7 million a year earlier and slightly above the consensus of about $123.0 million. Exome and genome revenue reached $110.4 million, up 12% year-over-year and up $10 million sequentially. The company resulted more than 32,100 exome and genome tests during the period.
On a generally accepted accounting principles (GAAP) basis, the company recorded a net loss of $12.3 million, or a loss of $0.41 per basic and diluted share. On an adjusted (non-GAAP) basis, which excludes items such as stock-based compensation, restructuring costs, and changes in the fair value of financial liabilities, GeneDx generated net income of $8.6 million, or $0.28 per diluted share — above the consensus estimate of $0.07 per share.
Adjusted gross margin improved to 72%, up from 70% in the second quarter, though down from 74% in the prior-year period. The blended average reimbursement rate (ARR) rose 5% sequentially to $3,436 per test, reflecting improved genome collections and a shift in product mix.
Management raised full-year adjusted gross margin guidance to about 71% and adjusted net income guidance to at least $12 million, while reaffirming total revenue guidance of $475 million to $490 million (expected at the low end). However, the company lowered its exome and genome volume growth target to at least 28% from 30%, and its exome and genome revenue growth outlook to at least 17% from 20%.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following GeneDx's earnings trajectory, the AI Screener can help identify comparable opportunities and emerging technical setups across the diagnostics and healthcare space.
GeneDx shares finished the regular session higher before reversing lower in after-hours trading following the release, as investors weighed the improving margin and profitability trend against the trimmed growth targets. The divergence reflects the core tension in the story: adjusted gross margin rose for a third consecutive quarter and adjusted net income turned positive, yet the company's decision to prioritize paid volume over raw volume — by requiring more payer documentation before testing begins — slowed reported test growth and prompted a downward revision to exome and genome targets. The initial reaction suggests the market remains focused on the near-term volume deceleration, even as management frames the shift as foundational to durable, higher-quality growth in 2027 and beyond.
Looking ahead, GeneDx expects fourth quarter 2026 revenue of at least $135 million, exome and genome revenue of $121 million, result volume of 34,500 tests, adjusted gross margin of at least 71%, adjusted net income of about $12 million, and an average reimbursement rate of approximately $3,500 per test.
Investors should monitor several factors in the coming quarters. First is the progress of the RCM transformation: management has said substantially all of the gap between accession growth (28%) and reported volume growth (25%) should eventually pull through as documentation processes become more efficient. Second is reimbursement risk, including the expected mid-single-digit revenue headwind from PAMA (the Protecting Access to Medicare Act) in 2027, which the company believes can be offset by improving collection rates.
Additional watchpoints include product mix, as genome's share of outpatient insurance-based volume fell to 26% from 32% sequentially; genome cost per test, which fell 43% year-over-year and is expected to decline further; and payer coverage expansion, including Medicaid's growing footprint and commercial plans adopting broader genome policies. The company has not yet provided formal 2027 guidance, but has signaled a positive trajectory and expects the general pediatrician segment to drive meaningful volume growth next year.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry MedicalSpecialties